Wytske J. Fokkens
YOU?
Author Swipe
View article: “Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps Open
Background Dupilumab is effective in treating patients with type‐2 dominant chronic rhinosinusitis with nasal polyps (T2‐CRSwNP). Dosing starts at an interval of 1×/2 weeks (Q2W) with possible tapering upon disease control. Prolonging the …
View article: Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry
Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry Open
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with type 2 inflammation. While biologics are a promising treatment for patients with uncontrolled CRSwNP, real-world evid…
View article: Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)
Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR) Open
Background Primary chronic rhinosinusitis (CRS) can be classified based on the sinuses involved and the dominant endotype of the mucosal inflammation. Since the introduction of type 2 targeted biologics as treatment option for CRS, assessm…
View article: Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease
Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease Open
Background Patients with Non‐steroidal anti‐inflammatory drugs ( NSAID )‐Exacerbated Respiratory Disease (N‐ ERD ) can suffer from difficult‐to‐treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps ( CRSwNP ). This study ev…
View article: Otitis Media With Effusion (<scp>OME</scp>) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An <scp>EAACI</scp> Position Paper
Otitis Media With Effusion (<span>OME</span>) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An <span>EAACI</span> Position Paper Open
IgE‐mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the “unified airways” concept vi…
View article: Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review
Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review Open
Background: Dupilumab shows promising results in the management of several type 2 disorders. However, it often leads to transient, early increases in blood eosinophil count (BEC). This has led to awareness of possibly associated eosinophil…
View article: Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024 Open
In April 2024, the European Summit “ Raising the bar in respiratory care” was organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) in the European Parliament and hosted by Members of the Europ…
View article: Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study Open
Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone …
View article: EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR
EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR Open
Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years of guidelines, AR remains largely under- d…
View article: Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis
Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis Open
status: Published
View article: Recent advances in chronic rhinosinusitis: pathophysiology, treatments, and outcome measures
Recent advances in chronic rhinosinusitis: pathophysiology, treatments, and outcome measures Open
This review discusses major developments in chronic rhinosinusitis. The latest papers on prevalence of the disease, the burden for patients and society, the lack of awareness, the development of patient classifications and the consequences…
View article: International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors Open
BACKGROUND: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Stateme…
View article: Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative Review
Reduced Sense of Smell in Patients with Severe Chronic Rhinosinusitis and its Implications for Diagnosis and Management: A Narrative Review Open
Reduced sense of smell is a common symptom in patients with chronic rhinosinusitis (CRS). Although it is often under-diagnosed by healthcare providers, reduced sense of smell can have a substantial negative impact on patient's quality of l…
View article: The epithelial barrier theory and its associated diseases
The epithelial barrier theory and its associated diseases Open
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial…
View article: Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab
Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab Open
ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52).
View article: Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison Open
Dupilumab was associated with greater improvements in CRSwNP-related outcomes versus mepolizumab.
View article: The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA
The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA Open
Background: The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact…
View article: Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP
Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP Open
Most patients with CRSwNP achieve clinically meaningful responses to dupilumab by week 16, and most such patients in our study had maintenance and durability of response with continued treatment over time.
View article: More than half of CRSwNP patients treated with dupilumab experience olfactory improvement within 28 days
More than half of CRSwNP patients treated with dupilumab experience olfactory improvement within 28 days Open
More than half of CRSwNP patients treated with dupilumab experience olfactory improvement within 28 daysTo the Editor, Olfactory dysfunction is one of the main complaints of patients suffering from Chronic Rhinosinusitis with Nasal Polyps,…
View article: How to be a good reviewer: A step‐by‐step guide for approaching peer review of a scientific manuscript
How to be a good reviewer: A step‐by‐step guide for approaching peer review of a scientific manuscript Open
Objectives The peer review process is critical to maintaining quality, reliability, novelty, and innovation in the scientific literature. However, the teaching of scientific peer review is rarely a component of formal scientific or clinica…
View article: Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study
Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study Open
Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.